Back to search
FDAFDA · Food and drugs·Recall number D-0442-2017

Temozolomide Capsules, 140 mg, packaged in a) 5-count bottles (NDC 0378-5263-98), b) 14-count bottles (NDC 0378-5263-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.

Published February 1, 2017 · Recall initiated: December 20, 2016

Summary

FDA records drug Class II recall D-0442-2017, published February 1, 2017 and initiated December 20, 2016. Recalling firm: Mylan LLC.; Status: Terminated; Reported quantity: a) 746 bottles (lot 2006903); b)588 bottles (lot 2006902); Lot: LOT #: a) 2006903, Exp 02/18; b) 2006902, Exp 02/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan LLC.
Distributor
Nationwide in the USA
Lot
LOT #: a) 2006903, Exp 02/18; b) 2006902, Exp 02/18
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Temozolomide Capsules, 140 mg, packaged in a) 5-count bottles (NDC 0378-5263-98), b) 14-count bottles (NDC 0378-5263-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA. recalled?

Yes. FDA published recall D-0442-2017 on February 1, 2017. Reported hazard: Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

What should I do if I have this product?

Voluntary: Firm initiated